On Tuesday, September 11, 2007, the American Association of Kidney Patients (AAKP) testified before the Food and Drug Administration’s (FDA) joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The committees discussed updated information on the risks and benefits of erythropoeisis-stimulating agents (ESAs) when used in the treatment of anemia due to chronic renal failure. [click link for full article]